157 related articles for article (PubMed ID: 27055285)
1. The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.
Chae YK; Gagliato Dde M; Pai SG; Carneiro B; Mohindra N; Giles FJ; Ramakrishnan-Geethakumari P; Sohn J; Liu S; Chen H; Ueno N; Hortobagyi G; Gonzalez-Angulo AM
PLoS One; 2016; 11(4):e0152585. PubMed ID: 27055285
[TBL] [Abstract][Full Text] [Related]
2. cMET and phospho-cMET protein levels in breast cancers and survival outcomes.
Raghav KP; Wang W; Liu S; Chavez-MacGregor M; Meng X; Hortobagyi GN; Mills GB; Meric-Bernstam F; Blumenschein GR; Gonzalez-Angulo AM
Clin Cancer Res; 2012 Apr; 18(8):2269-77. PubMed ID: 22374333
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Sheridan W; Scott T; Caroline S; Yvonne Z; Vanessa B; David V; Karen G; Stephen C
Breast Cancer Res Treat; 2014 Oct; 147(3):617-29. PubMed ID: 25209005
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma.
Mesteri I; Schoppmann SF; Preusser M; Birner P
Eur J Cancer; 2014 May; 50(7):1354-60. PubMed ID: 24565853
[TBL] [Abstract][Full Text] [Related]
8. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.
Koletsa T; Kotoula V; Karayannopoulou G; Nenopoulou E; Karkavelas G; Papadimitriou CS; Kostopoulos I
Histol Histopathol; 2010 Sep; 25(9):1171-9. PubMed ID: 20607659
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
[TBL] [Abstract][Full Text] [Related]
10. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
11. Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer.
Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Omoto Y; Iwase H
Int J Oncol; 2015 May; 46(5):2143-53. PubMed ID: 25738887
[TBL] [Abstract][Full Text] [Related]
12. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
Gorshein E; Klein P; Boolbol SK; Shao T
Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
[TBL] [Abstract][Full Text] [Related]
15. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
16. Expression of activated type I receptor tyrosine kinases in early breast cancer.
Spears M; Pederson HC; Lyttle N; Gray C; Quintayo MA; Brogan L; J Thomas JS; Kerr GR; Jack WJ; Kunkler IH; Cameron DA; Chetty U; Bartlett JM
Breast Cancer Res Treat; 2012 Jul; 134(2):701-8. PubMed ID: 22562124
[TBL] [Abstract][Full Text] [Related]
17. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
20. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
